Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aethlon Medical, Inc. (AEMD : NSDQ)
 
 • Company Description   
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

Number of Employees: 9

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.24 Daily Weekly Monthly
20 Day Moving Average: 289,231 shares
Shares Outstanding: 2.59 (millions)
Market Capitalization: $3.21 (millions)
Beta: 1.69
52 Week High: $8.44
52 Week Low: $1.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -54.07% -56.56%
12 Week -54.41% -61.75%
Year To Date -81.98% -83.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11555 SORRENTO VALLEY ROAD SUITE 203
-
SAN DIEGO,CA 92121
USA
ph: 619-941-0360
fax: -
susan@sanoonan.com http://www.aethlonmedical.com
 
 • General Corporate Information   
Officers
James B. Frakes - Chief Executive Officer and Chief Financial Office
Edward G. Broenniman - Chairman
Chetan S. Shah - Director
Angela Rossetti - Director
Nicolas Gikakis - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-HMO
Sector: Medical
CUSIP: 00808Y505
SIC: 3841
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 2.59
Most Recent Split Date: 6.00 (0.13:1)
Beta: 1.69
Market Capitalization: $3.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.53 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 90.51%
vs. Previous Quarter: 35.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -221.38
12/31/24 - -153.96
ROA
06/30/25 - -
03/31/25 - -156.83
12/31/24 - -109.13
Current Ratio
06/30/25 - -
03/31/25 - 3.13
12/31/24 - 2.80
Quick Ratio
06/30/25 - -
03/31/25 - 3.13
12/31/24 - 2.80
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.55
12/31/24 - 2.48
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©